Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine

Data on the efficacy of three SARS-CoV-2 mRNA BNT162b2 vaccine doses and the role of previous SARS-CoV-2-infection in enhancing vaccine immunogenicity in HIV-vertically-infected people living with HIV (PLWH) are limited, as is the duration of vaccine-induced responses. SARS-CoV-2 plasma neutralizing...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in immunology Ročník 14; s. 1301766
Hlavní autoři: Vanetti, Claudia, Stracuzzi, Marta, Crivellaro, Elisa, Ciciliano, Federica, Garziano, Micaela, Fenizia, Claudio, Biasin, Mara, Rubinacci, Valeria, Amendola, Antonella, Tanzi, Elisabetta, Zuccotti, Gian Vincenzo, Clerici, Mario, Giacomet, Vania, Trabattoni, Daria
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media SA 2023
Frontiers Media S.A
Témata:
Adult
Antiretroviral therapy
BNT162 Vaccine
CD4 antigen
CD8 antigen
Cell-mediated immunity
COVID-19 - prevention & control
COVID-19 SIV individuals
COVID-19 Vaccines
Enrollments
HIV
HIV Infections
Human immunodeficiency virus
Humans
Immune response
Immune response (cell-mediated)
Immune response (humoral)
Immunity (Disease)
Immunity, Cellular
immunocompromised subjects
Immunogenicity
Immunological memory
Immunology
Lymphocytes T
Memory cells
mRNA
Observational studies
Peptides
Plasma
PLWH
RNA, Messenger
SARS-CoV-2
SARS-CoV-2 vaccine efficacy
Severe acute respiratory syndrome coronavirus 2
Vaccines
Viral infections
Viremia
γ-Interferon
United States > US
Italy
Germany
PLWH
immunocompromised subjects
immune response
COVID-19 SIV individuals
SARS-CoV-2 vaccine efficacy
ISSN:1664-3224, 1664-3224
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Data on the efficacy of three SARS-CoV-2 mRNA BNT162b2 vaccine doses and the role of previous SARS-CoV-2-infection in enhancing vaccine immunogenicity in HIV-vertically-infected people living with HIV (PLWH) are limited, as is the duration of vaccine-induced responses. SARS-CoV-2 plasma neutralizing activity (NA) against the European (B.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants and cell-mediated immunity (CMI) were analyzed in 29 ART-treated young PLWH (mean age 27.9 years) and 30 healthy controls (HC) who received three BNT162b2 vaccine doses. Individuals were stratified based on the presence/absence of previous SARS-CoV-2 infection (infected and vaccinated -SIV-; uninfected and vaccinated -SV-). Analyses were performed before vaccination (T0), 25 days from the second dose (T1), the day the third dose was administered (T2), and 3 months after the third dose (T3). In PLWH: i) NA against all variants was higher in SIV compared to SV at T2 and was increased at T3; ii) switched-memory plasmablasts were augmented in SIV alone at T2 and T3; iii) a SARS-CoV-2 specific T cell memory was generated; iv) IFN-γ-secreting CD4+ and CD8+ T lymphocytes were boosted at T3 mainly in SV. CMI magnitude was reduced in PLWH compared to HC. Notably, after the third dose of vaccine viremia was unmodified, but CD4 T cell counts were reduced>20% in 3/29 PHLW. A third dose of BNT162b2 vaccine induces strong humoral and CMI responses in young ART-treated PLWH independently from a previous SARS-CoV-2 natural infection. The lower magnitude of CMI responses should be considered when planning mRNA vaccine booster doses in PLWH.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1301766